Langasog, Fe L.
HRN: 18-87-84 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/07/2025
CEFTAZIDIME 1GM (VIAL)
06/07/2025
06/13/2025
IV
500 Mg
OD
Sepsis Sec To Infected Wound
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft TissueCardiovascular Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes